分子胶质母细胞瘤前瞻性II期试验:治疗强化、边缘缩减与表观遗传分层初步分析
本II期试验纳入25例分子胶质母细胞瘤患者,放疗60Gy仅照GTV,CTV边缘可小至1cm,74%接受同步放化疗加辅助化疗。9例表观遗传分型中5例为间质亚型,其mOS为15.7个月,其他表型为37.7个月,提示分子胶质母细胞瘤存在异质性。
要点
- 分子胶质母细胞瘤放疗可仅照GTV 60Gy,CTV边缘可缩减至1cm。
- 间质亚型mOS为15.7个月,其他表型为37.7个月,提示预后异质。
- 74%患者接受同步放化疗加辅助化疗,治疗强化可行。
核心结论
- 分子胶质母细胞瘤群体存在内在异质性,间质亚型预后较差。
- 缩减CTV并强化治疗在非强化分子胶质母细胞瘤中可行。
研究设计与样本
- 前瞻性II期临床试验,2019至2023年纳入25例分子胶质母细胞瘤患者。
- 放疗60Gy仅照GTV,CTV边缘可小至1cm,74%接受同步放化疗加辅助化疗。
- 9例术前组织行Infinium EPIC平台表观遗传/DNA甲基化分型。
主要发现
- 25例中23例经二次复核为2级和3级疾病。
- 9例分型中5例为间质亚型,4例匹配其他表型包括新型F型GBM。
- 间质亚型mOS为15.7个月(95% CI 15.5-NA),其他肿瘤mOS为37.7个月(95% CI 10.9-NA)。
临床怎么用
- 非强化分子胶质母细胞瘤放疗可考虑仅照GTV 60Gy并缩减CTV边缘至1cm。
- 可结合表观遗传分型进行风险分层探索。
局限性
- 试验仍在进行中,本文报告探索性生物标志物分析。
- 仅9例患者有表观遗传分型数据,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Molecular glioblastoma (molGBM) is a variant lacking the full histopathological profile of glioblastoma. We report a trial aimed at addressing the optimal management of this newly recognized rarer form of glioma. METHODS: In this phase II study, molGBM patients were treated with radiation to a dose of 60Gy to the gross tumor volume (GTV) only, and a single smaller margin potentially as low as 1cm to the clinical tumor volume (CTV). As the trial is ongoing, we report on important exploratory biomarker findings correlating with median overall survival (mOS). Analysis included Kaplan-Meier and univariable/multivariable cox proportional hazard models. Available pre-operative tissue was subjected to epigenetic/DNA methylation profiling on the Infinium EPIC platform. RESULTS: From 2019 to 2023, 25 patients were enrolled based on initial pathology review, with 23 identified on 2nd review as grade 2 and 3 disease. 74% of patients received concurrent chemoradiotherapy with adjuvant chemotherapy. Of 9 patients with profiling, 5 were classified as mesenchymal subtype, while 4 matched to a variety of other phenotypes, including a novel F type GBM. Despite similar histological appearance corresponding to "lower grade glioma", molGBM classified as IDH-wildtype mesenchymal had mOS of 15.7 months (95% CI 15.5-NA) while the other tumors had a mOS of 37.7 months (95% CI 10.9-NA). CONCLUSION: Our results demonstrate underlying heterogeneity within the molGBM population, pointing to future hypothesis-generating risk stratification strategies. We also demonstrate the feasibility of CTV reduction with therapy intensification to set a practice standard for RT management of non-enhancing molGBM.
引用
- Yeboa DN, Whitfield BT, Lin R, et al. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy. J Neurooncol. 2025. PMID: 41191157. doi:10.1007/s11060-025-05269-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。